Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Giant planum sphenoidale meningioma: rationale for Dolenc's step in the pterional approach.

Neurosurgical focus: Video·2026
Same author

mGem: AAV, from almost a virus to an awesome vector-or is it?

mBio·2026
Same author

Total and Neutralizing Antibody Seroprevalence of Hepatotropic Adeno-Associated Virus Among Healthy and Hemophilia A or B Population from India.

Human gene therapy·2025
Same author

Changing Spectrum of Invasive Fungal Infections of the Anterior Skull Base.

Journal of neurological surgery. Part B, Skull base·2024
Same author

Outcomes following surgical clipping of re-ruptured previously untreated intracranial aneurysms.

Neurosurgical review·2024
Same author

AAV vectors for long-term gene therapy of hemophilia B: Are we there yet?

Molecular therapy : the journal of the American Society of Gene Therapy·2024

Related Experiment Video

Updated: Dec 31, 2025

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
09:12

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Published on: April 5, 2024

4.2K

Adeno-associated virus-mediated gene transfer.

Arun Srivastava1

  • 1Division of Cellular & Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida 32610-3633, USA. aruns@peds.ufl.edu

Journal of Cellular Biochemistry
|May 27, 2008
PubMed
Summary

Recombinant adeno-associated virus 2 (AAV2) vectors show promise for hematopoietic stem cell (HSC) gene therapy. Novel AAV vectors and strategies enable efficient HSC transduction, with stable genome integration observed in preclinical models.

More Related Videos

Author Spotlight: Unveiling the Potential of Unpurified Recombinant AAVs in Cell Culture Research
06:41

Author Spotlight: Unveiling the Potential of Unpurified Recombinant AAVs in Cell Culture Research

Published on: October 20, 2023

3.9K
Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane
07:32

Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane

Published on: March 16, 2015

17.0K

Related Experiment Videos

Last Updated: Dec 31, 2025

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
09:12

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Published on: April 5, 2024

4.2K
Author Spotlight: Unveiling the Potential of Unpurified Recombinant AAVs in Cell Culture Research
06:41

Author Spotlight: Unveiling the Potential of Unpurified Recombinant AAVs in Cell Culture Research

Published on: October 20, 2023

3.9K
Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane
07:32

Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane

Published on: March 16, 2015

17.0K

Area of Science:

  • Gene Therapy
  • Molecular Biology
  • Virology

Background:

  • Recombinant adeno-associated virus 2 (AAV2) vectors are versatile for in vitro and in vivo gene delivery.
  • Controversies exist regarding AAV2 vector efficacy in hematopoietic stem cell (HSC) transduction.
  • Recent advancements are clarifying molecular bases and improving AAV vector applications.

Purpose of the Study:

  • To address controversies surrounding AAV2 vector efficacy in HSC transduction.
  • To explore novel AAV serotypes and vector design strategies for efficient HSC transduction.
  • To investigate the in vivo integration and safety of AAV genomes in HSCs.

Main Methods:

  • Utilized a murine serial bone marrow transplantation model.
  • Employed novel AAV serotypes and capsid mutants.
  • Investigated self-complementary vector genomes and hematopoietic cell-specific promoters.

Main Results:

  • Demonstrated stable integration of the proviral AAV genome into mouse chromosomes.
  • Observed no overt hematological abnormalities following AAV genome integration.
  • Showcased the feasibility of efficient HSC transduction using advanced AAV vector strategies.

Conclusions:

  • Improved understanding of AAV-HSC interactions is crucial for gene therapy.
  • Novel AAV serotypes and capsid mutants enhance HSC transduction efficiency.
  • AAV vectors hold significant potential for hematopoietic system gene therapy applications.